NHS BT Flashcards

1
Q

Blood group antibodies

A

In Transfusion there are two classes of immunoglobulin which are of interest as far as blood group antibodies are concerned
IgM
IgG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

IgM

A

Pentameric structure (MW c. 900,000)
10 antigen binding sites
Red cells repel one another and do not come closer than within 12 nm of one another
A single IgM antibody can bridge the gap and cause agglutination of red cells

Work best at temperatures below 37oC
Are generally of minor clinical significance
May bind complement
Do not cross the placenta
ABO blood group antibodies are mainly IgM (yet are highly clinically significant)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

IgG

A

Monomeric structure (MW c. 180,000)
2 antigen binding sites
Binding site can only reach 10 nm apart
A single IgG antibody cannot cause agglutination of red cells

Work best at 37oC
Generally of clinical significance
Do not usually bind complement
Are able to cross the placenta
Primarily cause the removal of red cells by extravascular haemolysis (Fc regions of red cell bound IgG interacts with Fc Receptors on macrophages of reticuloendothelial system)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

ABO groups in UK

A

Group O 47%
Group A 42%
Group B 8%
Group AB 3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

ABO Genes

A

The presence of the A and B blood groups is
governed by three genes which encode for
glycosyltransferase enzymes

H gene Located on Chromosome 19
A gene Located on Chromosome 9
B gene Located on Chromosome 9

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Blood Group A Genotype

A

AA AO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Blood Group B Genotype

A

BO BB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Blood Group AB Genotype

A

AB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Blood Group O Genotype

A

OO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

ABO subgroups

A

A1 – 80%
A2 – 20%

Is quantitative difference, but may be qualitative in some cases where anti-A1 is produced.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Blood Group A1 Genotype

A

A1A1, A1A2, A1O

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Blood Group A2 Genotype

A

2A2, A2O

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Blood Group A2B

A

A2B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

ABO Antibodies

A

Present in the general population
“Naturally” occurring
Not present at birth
Develop over the first four months after birth

Some immunoglobulin just happens to ‘fit’ (c.f. Lectins)
Via maternal milk
From environmental factors (Experiments with chickens)
Genetic basis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Landsteiners Law

A

ABO antibodies are found in the plasma against the ABO antigens an individual lacks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Landsteiners Law Blood Groups

A
Blood Group	    Antigen on		  Antibody in
				    red cells		  plasma
		O		      None		    Anti-A + B
		A		         A		    Anti-B
		B		         B		    Anti-A
		AB		      A and B	        	    None
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Development of ABO Ag and Abs

A
Antibodies
Not present at birth
Development during first 4 months
Reach maximum strength at 5 yrs old 
Antigens
Not fully developed at birth
Development over first 1 - 2 yrs of life
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Clinical significance of ABO

A

IgM antibodies
Work best at low temperatures

But…….
Highly clinically significant
Cause intravascular haemolysis (complement activation)
May cause fatal reaction in cases of incompatible transfusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Antibody Identification ISBT View

A

No antibody investigation technique or combination of techniques can be guaranteed to detect all red cell antibodies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Red Cell Ab Panel

A
Identify a single antibody
Separate common mixtures
If possible in a single pass
Not give the same pattern of results with two different antibodies
Give “confidence” in the findings
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Panel Cells

A

Panel cells
usually cell samples from 10 selected donors
stored liquid in preservative solution

Reactivity in vitro is a surrogate marker for red cell destruction in vivo

All group O  
Include R1R1 (Cde) and R1wR1
Include R2R2 (cDE), r’r (Cde) and r”r (cdE)
3 rr (cde) homozygous expression of k, Fya, Fyb, Jka, Jkb, S, s and also express K
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q



BCSH* Guidelines for Compatibility Procedures.

A

“When an alloantibody is detected in the screening procedure its specificity should be determined and its clinical significance assessed”

Transfusion Medicine 14 59-73 2004

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q




Antibody risk assessment
for transfusion SIGNIFICANT

A
Significant
ABO
Rh (all of them!)
Kell system
Kidd system
Duffy system
anti-M 37oC active
Anti-S, -s
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q




Antibody risk assessment
for transfusion Insignificant

A
anti-Lea
anti-Leb
anti-P1
anti-H(I) (Not anti-H in “Bombay” phenotype)
anti-N
anti-M (20oC only)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Indirect Antiglobulin Technique
detects 37oC active antibodies detects IgG antibodies detects complement fixing antibodies Detects all Rh antibodies, anti-K, k, Fya, Fyb, Jka, Jkb, M (reactive at 37 deg C), S, s, Kpa, Kpb, Lua, Lub “The gold standard”
26
Enzyme treated cell techniques (Papain)
good for all Rh antibodies and anti-Jka, Jkb, Lea, Leb, P1 does not detect anti-Fya, -Fyb, -M, -N, -S because these blood groups are destroyed by papain treatment excellent in resolving mixtures
27
Saline 20oC
detects IgM antibodies, e.g anti-M, N, P1, Lea, Leb, H, I and ABO detects antibodies which are usually clinically insignificant (ABO antibodies excepted) detects antibodies which may give unclear IAT good for resolving mixtures
28

Tools of the trade: other techniques
PEG IAT, 2-stage IAT, enzyme IAT, Capture R, albumin displacement, polybrene, 37oC saline, 31oC saline 4oC saline, NISS, LISS, BLISS, adsorptions, elutions, neutralisations………….
29

BCSH Guidelines for Compatibility Procedures.
“The specificity of the antibody should only be assigned when it is reactive with at least two examples of reagent cells carrying the antigen and non reactive with two examples lacking the antigen”
30
Identification criteria
To be certain of the identification of an antibody the panel used must give Positive results against two cells which contain the antigen Negative results against two cells which lack the antigen Exclude the presence of any other antibodies
31
Antibody ID tips
Enzyme sensitive (don’t work with papain-treated cells) helps to resolve mixtures: anti-M, -N, -S, -s, -Fya, -Fyb Dosage: stronger reactions with homozygous cells (~twice as much antigen on cells) anti-Fy, -Jk (especially), MNSs, anti-c, -D (anti-D may react stronger with R2R2 cells) IgM antibodies (20oC active): anti -M,-N,-P1, -Lea,-Leb Masked antibodies Expect the expected!
32

Antibody mixtures:
How do you know it’s a mix?
No fit for a single specificity, auto negative ? Different strengths of reactions ? Different patterns with different techniques? Additional reactions to those in previous sample
33

How to identify elements of a mixture
``` Getting some negative results? Try to identify at least one component (there’s usually some Rh in there) Use negatives to eliminate something! Try to find more negatives (more panels) ``` Performing a patient phenotype can help (ABO, D, C, E, c, e, Cw, MNSs, P1,Lea, Leb, K, (k if K+), Kpa(Kpb if Kpa+), Fya, Fyb ,Jka, Jkb How does the phenotype help? Tells you what alloantibodies patient can form Helps you to find more panel cells May help in providing safe transfusion BUT BEWARE The transfused patient The “untransfused” patient The Positive Direct Antiglobulin Test
34
Indirect Antiglobulin Test
IAT Antigen – Antibody complex forms AHG added (Anti-Human Globulin) Agglutination seen
35
Molecular RBC typing
Can provide a full genetic type for highly prevalent antigens Simple 3 step procedure with minimal ‘hands-on’ time, giving results in under 3 hours Most technology (PCR cyclers) already present in H&I laboratories Specialised Reader
36
Clinical Value of Molecular RBC typing
``` DAT positive patients Multi-transfused patients Patients with pan-reactive autoantibody that resists absorption procedures Patients with weak expression of antigen Where liquid reagents are unavailable ```
37
RBC genotyping
Extract DNA (30 mins) Prepare tests - microplate (10-30 mins) Amplify DNA – thermocyclers (c2 hours) Analysis (10 mins)
38
Taqman Probe PCR SSP
....
39
Taqman Workflow
Samples processed in a single day 3 Samples per run, up to 8 runs a day Results available in approx 2.5 hours Good reliability with low failure rate
40
RBC FluoGene Validation Results
``` Newcastle and Sheffield 1056 donor samples 6 fails (0.6%) – All resolved on repeat 7 ‘indeterminate’ single types – 4 resolved on repeat ``` Similar findings in routine processing of samples
41
Patient Evaluation for Genotyping
AIHA DAT positive Antibody combinations/SNDT Ethnic representation
42
RBC Genotyping Advantages
Most useful in multi-transfused and AIHA cases Results can be obtained the same day Reproducible, Low fail rate Good concordance with serological typing results Simple to use and not labour intensive No significant wastage Direct download of results
43
RBC Genotyping Disadvantages
Not suitable for urgent cases Not as fast as serological typing (see urgent cases above) Not suitable for rare genotypes – require sequencing ABO – simple serologically but complex genetically (not performed on this assay).
44
RBC Genotyping COnclusiona
Genotyping improves ability to provide patients with suitable blood. Costs currently prohibit routine use for all patients. Likely greater use in future for both donors and patients ``` CE marking Direct download Reporting (Hematos / SP-ICE) Price What we do with the info; Recommendations Selection of blood ```
45
Rh blood group system History
Landsteiner and Wiener (1941) found that an immune serum produced in guinea pigs immunised with blood from Rhesus monkeys reacted with red cells from 85% of the New York population. They named this new finding the ‘Rhesus factor’ 85% were ‘Rhesus’ pos, 15% were ‘Rhesus’ neg It was discovered that all Levine & Stetson’s women were ‘Rhesus’ negative and all their husbands were ‘Rhesus’ positive Following this discovery (and the subsequent confirmatory work) it was proposed that all ‘Rhesus’ negative people should be transfused ‘Rhesus’ negative blood.
46
Rh D Antigen
The Rh system comprises five commonly occurring antigens. The most important one is called D The RhD gene is found on chromosome no 1 Defines Rh status in donors and patients The unlinked RhAG gene on chromosome 6 incorporates the antigen into the cell membrane D positive individuals have the RhD gene Most D negative individuals have an RhD gene deletion
47
RhD Uk Frequencies
85% RhD positive | 15% RhD negative
48
Rhesus Weak D
Weak D Formerly known as Du Possesses all normal D antigens, but has quantitatively less Is RhD positive as a donor, patient and an antenatal patient Cannot produce anti-D
49
Rh Partial D
Lacks part of a normal D antigen Can produce anti-D (as is missing some of the D antigen) Can cause the production of anti-D in a D negative recipient (as possess some of the D antigen) Regarded as RhD Pos as a donor RhD Neg as a recipient Antenatal patients require anti-D prophylaxis
50
Expanded Rh System
``` Composed of 5 commonly occurring antigens D C c E e ``` These 5 Rh antigens are inherited as a group of 3 antigens which are inherited together C and c antigens are alleles on the RHCE gene E and e antigens are alleles on the RHCE gene There is no d antigen, most RhD negative individuals lack the D antigen (have no RHD gene)
51
Rh Combinations
Antigens Short CDe R1 1st order cDE R2 1st order cde r 1st order Cde r’ 2nd order cdE r’’ 2nd order Antigens Short cDe Ro 1st order in blacks rare in whites CDE RZ Rare CdE ry Extremely rare
52
Rh Antibodies Anti D
Anti-D Anti-D is the most potent and remains a major cause of Haemolytic Disease of the Fetus and Newborn (HDFN) Produced in women as a result of sensitisation by red cells from D positive fetus May be produced in males as a result of transfusion with D positive blood.
53
Rh Antibodies Anti c
Clinically significant Relatively common May cause HDFN or Haemolytic Transfusion Reaction (HTR) Often found together with anti-E
54
Rh Antibodies Anti E
Anti-E ``` Clinically significant Relatively common May cause HDFN or HTR Less clinically significant than anti-c Often found together with anti-c in individuals who lack c and E antigens ```
55
Rh Antibodies Anti C
``` Anti-C Clinically significant Relatively common, often seen with anti-D May cause HTR HDFN rare when on its own ```
56
Rh Antibodies Anti e
Anti-e Clinically significant May cause HTR
57

Prevention of Rh antibody production
Type patients for full Rh group and match the donations This is important for: All female patients under 60 yrs of age Patients who may need regular transfusions (e.g. Sickle cell disease) Patients who have already produced other antibodies (‘responders’)
58

Haemolytic Disease of the Fetus and Newborn (HDFN)
A condition affecting fetuses and newborn infants caused by a blood group antibody in the mother attacking red cells in the infant which carry the corresponding antigen inherited from the father. The most potent form of the disease results when the mother is RhD negative and the fetus is RhD positive
59
First pregnancy post delivery
Mother is sensitised against foreign red cell antigens on fetus Antigens which are more fully developed on fetal cells are more likely to cause sensitisation (e.g. Rh, but not ABO)
60
Main causes of HDFN
``` Antibodies involved include Anti-D (or D + C) Anti-Kell Anti-c Anti-E Anti-Fya Other IgG antibodies e.g –S, -Jka, other anti-Rh ABO ```
61
Relationship between antibody 
strength and HDFN outcome
``` Theoretically: More IgG antibody in the maternal circulation = more crosses the placenta = more severe HDFN But… Moderate anti-D and anti-c Poor anti-K and anti-E Variable other specificities Useless ABO ```
62
Diagnosis and treatment of HDFN
Direct antiglobulin test (DAT) on cord blood. This detects IgG antibody bound to the surface of the infant’s red cells. A positive result is diagnostic of HDFN. Mild – Phototherapy under UV light Moderate – Top-up or exchange transfusion Severe – Exchange transfusion at birth or Intra-Uterine Transfusion (IUT) during pregancy
63


Treatment - Requirements for IUT / exchange transfusion red cells Intrauterine transfusion
``` 5 days old or less, CPD red cells CMV negative Sickle cell negative Negative for any red cell antibodies Low level of anti-A and anti-B Gamma irradiated Hct 0.5 – 0.6 for ET up to 0.7 for IUT ```
64
Prevention of HDFN – History
1960’s – Sir Cyril Clarke at Liverpool Known that ABO antibodies offered some protection Prevention began in 1970 (post-natal prophylaxis) Standard dose of prophylactic anti-D (polyclonal, human derived) 500 IU up to 4mL bleed 1500 IU up to 12mL bleed FMH calculated by Kleihauer test or Flow cytometry Antenatal prophylaxis Monoclonal anti-D (not as effective)
65
Significant antibody risk for HDFN
``` Significant Anti-D Anti-c Anti-K Other Rh Kidd system Duffy system anti-M (37OC), -S -s ```
66
Insignificant antibody risk for HDFN
``` Not significant •anti-Lea •anti-Leb •anti-P1 •anti-H(I) •anti-N •anti-M (20oC only) ```